Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma

Leukopenia and selective CD4+ lymphopenia represent major adverse events associated with the use of temozolomide (TMZ), an oral alkylating agent incorporated in the treatment of glioblastoma (GBM). The increased risk of opportunistic infections, including those caused by Pneumocystis jiroveci and cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Munhoz, Rodrigo Ramella, Pereira Picarelli, Andrea Arvai, Troques Mitteldorf, Cristina Aparecida, Feher, Olavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: August, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764971/
https://www.ncbi.nlm.nih.gov/pubmed/24019780
http://dx.doi.org/10.1159/000354429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764971/
https://www.ncbi.nlm.nih.gov/pubmed/24019780
http://dx.doi.org/10.1159/000354429

Ejemplares similares